Ensysce Biosciences, Inc.
ENSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $2 | $3 | $4 |
| % Growth | 133.5% | -11.6% | -28.5% | – |
| Cost of Goods Sold | $7 | $8 | $20 | $0 |
| Gross Profit | -$2 | -$5 | -$17 | $4 |
| % Margin | -38.6% | -240.1% | -686.1% | 100% |
| R&D Expenses | $7 | $8 | $20 | $5 |
| G&A Expenses | $5 | $5 | $7 | $0 |
| SG&A Expenses | $5 | $5 | $7 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7 | -$8 | -$20 | $0 |
| Operating Expenses | $5 | $5 | $7 | $23 |
| Operating Income | -$7 | -$11 | -$24 | -$20 |
| % Margin | -129.2% | -480.4% | -959.9% | -562.7% |
| Other Income/Exp. Net | -$1 | $0 | $0 | -$9 |
| Pre-Tax Income | -$8 | -$11 | -$24 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$11 | -$24 | -$29 |
| % Margin | -153.3% | -475.7% | -957.9% | -823.6% |
| EPS | -4.57 | -4.69 | -139.44 | -355.68 |
| % Growth | 2.6% | 96.6% | 60.8% | – |
| EPS Diluted | -4.57 | -4.69 | -139.44 | -355.68 |
| Weighted Avg Shares Out | 2 | 2 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 2 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $3 |
| Interest Expense | $1 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$7 | -$11 | -$24 | -$26 |
| % Margin | -129.2% | -480.4% | -959.9% | -734.3% |